| Multiple Myeloma
Elrexfio vs Sarclisa
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Elrexfio vs Sarclisa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSarclisa has a higher rate of injection site reactions vs Elrexfio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sarclisa but not Elrexfio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Elrexfio
Sarclisa
At A Glance
SC injection
Weekly to every 4 weeks
BCMA-directed T-cell engager
IV infusion
Every 1-4 weeks
CD38-directed cytolytic antibody
Indications
- Multiple Myeloma
- Multiple Myeloma
Dosing
Multiple Myeloma Step-up SC dosing: 12 mg on Day 1, 32 mg on Day 4, then 76 mg weekly starting Day 8 through week 24; for responders, transitions to 76 mg every 2 weeks (weeks 25-48), then 76 mg every 4 weeks (week 49 onward); continue until disease progression or unacceptable toxicity.
Multiple Myeloma (with pomalidomide and dexamethasone) 10 mg/kg IV weekly in cycle 1 (days 1, 8, 15, 22 of a 28-day cycle), then every 2 weeks (days 1, 15) from cycle 2 onward.
Multiple Myeloma (with carfilzomib and dexamethasone) 10 mg/kg IV weekly in cycle 1, then every 2 weeks from cycle 2 onward.
Multiple Myeloma (with bortezomib, lenalidomide, and dexamethasone) 10 mg/kg IV on days 1, 8, 15, 22, and 29 of cycle 1 (42-day cycle); every 2 weeks in cycles 2-17; every 4 weeks from cycle 18 onward.
Contraindications
—
- Severe hypersensitivity to isatuximab-irfc or any of its excipients
Adverse Reactions
Most common (>=20%) CRS, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, pyrexia
Serious Pneumonia, sepsis, CRS, upper respiratory tract infection, acute kidney injury, urinary tract infection, COVID-19, encephalopathy, pyrexia, febrile neutropenia
Most common (>=20%) Upper respiratory tract infection, infusion-related reactions, pneumonia, diarrhea, fatigue, hypertension, dyspnea, insomnia, bronchitis, cough, back pain, peripheral sensory neuropathy, musculoskeletal pain, cataract, constipation, peripheral edema, rash
Serious Pneumonia, upper respiratory tract infections, febrile neutropenia, cardiac failure
Pharmacology
Elranatamab-bcmm is a bispecific BCMA-directed CD3 T-cell engaging antibody that simultaneously binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells, leading to T-cell activation and cytolysis of BCMA-expressing cells.
Isatuximab-irfc is an IgG1-derived monoclonal antibody that binds to CD38 expressed on hematopoietic and tumor cells, inducing apoptosis and activating immune effector mechanisms including ADCC, ADCP, and CDC, while also inhibiting CD38 ADP-ribosyl cyclase activity and suppressing CD38-positive T-regulatory cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Elrexfio
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Sarclisa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Elrexfio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Sarclisa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Elrexfio
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Sarclisa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Multiple Myeloma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Multiple Myeloma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ElrexfioView full Elrexfio profile
SarclisaView full Sarclisa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.